PURPOSE: High-flow arteriovenous malformations (AVMs) are complex vascular lesions for which transcatheter embolization is considered as first-choice treatment nowadays. Multiple embolizing agents have been described, and among them, Onyx® seems to be promising; this is a liquid embolic agent, originally applied in neurointerventional radiology and recently adopted also in peripheral embolizations. The aim of this study is to report on a 10-year experience of transarterial embolization of peripheral high-flow AVM with Onyx® in terms of technical and clinical outcomes. MATERIALS AND METHODS: Retrospective analysis was conducted on patients affected by high-flow AVM and treated electively by transarterial embolization with Onyx®. Data collection included: preinterventional clinical radiological evaluations, procedural data and post-procedural clinical radiological assessment. Technical and clinical success was evaluated; follow-up was conducted 30 days after the last treatment session and yearly in case of success. RESULTS: Sixteen patients have been included, totally 38 embolizing procedures. Additional embolizing agents were required in 5 patients. Technical success was obtained in 11 patients; at 30-day follow-up, 15 patients showed improvements in symptoms, even those with incomplete embolization; however, after almost 1 year from treatment accomplishment, 7 patients showed relapse of symptoms and presented radiological signs of AVM recurrence. No clinically relevant complications occurred. CONCLUSIONS: In this series, in accordance with previous but limited published data, Onyx® appeared safe and technically effective to embolize high-flow peripheral AVM with transarterial approach. Clinical radiological follow-up is mandatory because new feeder recruitment has to be expected; patients should be informed of the concrete possibility of multiple treatment sessions.
PURPOSE: High-flow arteriovenous malformations (AVMs) are complex vascular lesions for which transcatheter embolization is considered as first-choice treatment nowadays. Multiple embolizing agents have been described, and among them, Onyx® seems to be promising; this is a liquid embolic agent, originally applied in neurointerventional radiology and recently adopted also in peripheral embolizations. The aim of this study is to report on a 10-year experience of transarterial embolization of peripheral high-flow AVM with Onyx® in terms of technical and clinical outcomes. MATERIALS AND METHODS: Retrospective analysis was conducted on patients affected by high-flow AVM and treated electively by transarterial embolization with Onyx®. Data collection included: preinterventional clinical radiological evaluations, procedural data and post-procedural clinical radiological assessment. Technical and clinical success was evaluated; follow-up was conducted 30 days after the last treatment session and yearly in case of success. RESULTS: Sixteen patients have been included, totally 38 embolizing procedures. Additional embolizing agents were required in 5 patients. Technical success was obtained in 11 patients; at 30-day follow-up, 15 patients showed improvements in symptoms, even those with incomplete embolization; however, after almost 1 year from treatment accomplishment, 7 patients showed relapse of symptoms and presented radiological signs of AVM recurrence. No clinically relevant complications occurred. CONCLUSIONS: In this series, in accordance with previous but limited published data, Onyx® appeared safe and technically effective to embolize high-flow peripheral AVM with transarterial approach. Clinical radiological follow-up is mandatory because new feeder recruitment has to be expected; patients should be informed of the concrete possibility of multiple treatment sessions.
Authors: Murat Cantasdemir; Fatih Gulsen; Serdar Solak; Gokce Yalcin Gulsen; Fatih Kantarci; Furuzan Numan Journal: Pediatr Surg Int Date: 2012-01-22 Impact factor: 1.827
Authors: M Saeed Kilani; J Izaaryene; F Cohen; A Varoquaux; J Y Gaubert; G Louis; A Jacquier; J M Bartoli; G Moulin; V Vidal Journal: Diagn Interv Imaging Date: 2015-02-18 Impact factor: 4.026
Authors: Karla Maria Eberhardt; Mojtaba Sadeghi-Azandaryani; Stefanie Worlicek; Thomas Koeppel; Maximilian F Reiser; Marcus Treitl Journal: J Endovasc Ther Date: 2014-02 Impact factor: 3.487
Authors: C Benjamin Newman; Min S Park; Charles W Kerber; Michael L Levy; John D Barr; R Sean Pakbaz Journal: J Neurointerv Surg Date: 2011-06-16 Impact factor: 5.836
Authors: Jessica Bowman; Jonathan Johnson; Michael McKusick; Peter Gloviczki; David Driscoll Journal: Semin Vasc Surg Date: 2013-03 Impact factor: 1.000